KRAS and frontotemporal dementia: In analyses restricted to the subgroup with KRAS mutations (n = 407 patients), KRASG12 mutations were also significantly associated with reduced OS benefit of FTD/TPI versus placebo (unadjusted interaction P = 0.0091; adjusted interaction P = 0.0037; full regression model fits shown in Supplementary Table 8).